CD95 (APO-1/Fas)/CD95L (APO-1L/FasL/CD178) is a receptor/cytokine pair of the tumor necrosis factor/nerve growth factor (TNF/NGF) superfamily. Similar to other receptors of this family, activation of CD95/Fas results in the formation of a death-inducing signaling complex (DISC) and subsequent activation of the apoptotic cascade [1] . There is increasing evidence that CD95/Fas also signals survival, proliferation, and migration in CD95/Fas-expressing cells that are resistant to CD95L/FasL-induced cell death [2, 3] . This non-apoptotic signaling of CD95/Fas is also referred to as "reverse signaling" [3] . In contrast to the apoptotic signaling cascade, the molecular mechanisms resulting in the activation of non-apoptotic pathways are still vague [3] .
The physiological role of CD95/Fas expression in the central nervous system is unknown. Both, CD95/Fas and CD95L/FasL have been detected in the brain [4] [5] [6] , but their spatial and temporal expression patterns change during development [5, 7] . Mice with defective CD95/Fas receptor (lpr-mice) or ligand (gld-mice) are protected in various animal models of acute neuronal damage, e.g. after ischemic stroke or spinal trauma [8, 9] . Zuliani and coworkers provided first evidence that CD95/Fas-mediated "reverse signaling" might mediate neuroregeneration in the CNS [10] . They could show that CD95/Fas did not induce apoptosis in cortical and hippocampal neurons but rather controlled branching of these neurons in vitro. In addition, the authors found a significant difference in the number of dendritic branches in mice deficient in CD95/ Fas and CD95L/FasL, suggesting an involvement of this mechanism during embryonic development. It is unknown whether CD95/Fas-controlled neuronal branching might be relevant in neurological diseases [10] . Because neuronal branching significantly contributes to neuroplasticity and therefore neurological recovery after acute neuronal damage, we speculated that CD95/Fas might be involved in the regeneration after traumatic brain injury (TBI). To test this hypothesis, we investigated the acute and chronic responses of CD95/Fas-deficient lpr-mice and wildtype control animals after controlled cortical impact (CCI).
CCI is a well-established animal model for TBI. It was performed using MRL-lpr mice and wildtype control animals with the same genetic background (composite genomic background: LG (75%), AKR/J (12.6%), C3H (12.1%), C57BL/6 (0.3%), Harlan UK Limited, Great Britain) as described previously (CCI: 2 mm flat-tip impounder; pressure: 25 kPa; depth: 1 mm, impact duration: 100 ms) [11] . Because MRL-lpr-mice develop systemic vasculitis at the age of 12 weeks [12] , we used 6-8-week-old animals for the experiments. No signs of vasculitis were seen on hematoxylin/eosin-stained slides. To rule out a subconscious investigator bias, CCI, histological evaluation, and behavioral tests were performed "blinded".
The CCI lesion was placed over the motor cortex causing direct damage of motor cortex and indirect, time-dependent cell death of hippocampal neurons ( Figure 1A) . We used the beam walking test [13] to determine locomotor deficits and the Morris water maze test [14] to monitor the hippocampal function. In line with previous results, lpr-mice performed significantly better in both tests during the first 72 h after Apoptotic neurons in the dentate gyrus of the hippocampus in wildtype animals were detected using the Apo-direct Kit (Chemicon, München, Germany) for TUNEL (Terminal Deoxynucleotidyl Transferase-mediated dUTP Nick End-Labeling) staining. The average number of apoptotic neurons in the dentate gyrus per slide at the time points indicated is given (n = 4 animals). (B) Morris water maze test: Mice (lpr n = 8, control n = 8) learned to find the position of an invisible platform in a black water tank (diameter: 1.05 m with white signs for orientation) on 3 consecutive days before CCI. After CCI, the mice had to find the platform within 60 s, where they were allowed to sit for 10 s (5 cycles per timepoint). The platform position remained unchanged during the entire experiment; the mouse was placed randomly in the tank. If the mouse did not find the platform within 60 s, it was placed on the platform for 10 s to enable it to memorize its position. The average latency until the mice found the platform is shown. In all, 6 trials per time point and animal were performed. We did not conduct the Morris water maze test 24 h after CCI to avoid wound infections. (Figure 1B and 1C) . The reduced neurological deficits were paralleled by a significantly reduced number of TUNEL-positive hippocampal neurons in lpr-as compared with wildtype mice 24 h after CCI ( Figure 1D ). We further tested the mice until 21 days after the trauma. As compared with lpr-mice, wildtype mice had enduring and more pronounced locomotor deficits ( Figure 1C) due to the direct damage of the motor cortex and subsequent larger lesions ( Figure 1E ) with less remaining brain tissue ( Figure 1F) . Notably, wildtype mice that had performed worse in the Morris water maze test directly after CCI improved their spatial memory function faster and better as compared with lpr-mice ( Figure 1B) .
The Morris water maze test determines the spatial memory function and the performance correlates with the integrity of hippocampal neurons that strongly express CD95/Fas [5, 14] . The impaired improvement of the spatial memory function of lpr-mice after CCI therefore implies a functional relevance of the "death receptor" CD95/Fas expression on hippocampal neurons. Because neuronal branching is a major mediator for regeneration and subsequent functional recovery, it appears likely that CD95/Fas-mediated neuronal branching is involved in the cognitive improvement after CCI [10] . Our results therefore complement the in vitro data published by Zuliani et al. and suggest a functional relevance of CD95/Fas-mediated neuronal branching in this paradigmatic animal model. CD95/Fas has a two-facet role in the pathogenesis of TBI. It is detrimental directly after the trauma and seems to become a mediator of regeneration by mediating neuronal branching in the later course of the disease. These conflicting functions are most likely mediated by regulatory proteins (e.g. LFG or c-FLIP) that are expressed in the hippocampus [6, 15] and regulated after TBI [15] . Therefore, targeting these proteins might be an excellent therapeutic approach for TBI aiming to inhibit apoptotic neuronal death initially and to promote neuronal recovery later on.
